212 related articles for article (PubMed ID: 35797592)
21. Sphingosine kinase 1 is overexpressed and promotes adrenocortical carcinoma progression.
Xu Y; Dong B; Huang J; Kong W; Xue W; Zhu Y; Zhang J; Huang Y
Oncotarget; 2016 Jan; 7(3):3233-44. PubMed ID: 26673009
[TBL] [Abstract][Full Text] [Related]
22. Potentiation of mitotane action by rosuvastatin: New insights for adrenocortical carcinoma management.
Boulate G; Amazit L; Naman A; Seck A; Paci A; Lombes A; Pussard E; Baudin E; Lombes M; Hescot S
Int J Oncol; 2019 Jun; 54(6):2149-2156. PubMed ID: 30942448
[TBL] [Abstract][Full Text] [Related]
23. The Efficacy of Mitotane in Human Primary Adrenocortical Carcinoma Cultures.
van Koetsveld PM; Creemers SG; Dogan F; Franssen GJH; de Herder WW; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2020 Feb; 105(2):407-17. PubMed ID: 31586196
[TBL] [Abstract][Full Text] [Related]
24. Use of a levonorgestrel-releasing intrauterine device for menorrhagia treatment during adjuvant therapy of adrenocortical carcinoma with mitotane.
Szkodziak PR; Czuczwar P; Woźniak S; Szkodziak F; Paszkowski T
Ginekol Pol; 2017; 88(10):576-577. PubMed ID: 29192420
[TBL] [Abstract][Full Text] [Related]
25. Effects of mitotane on the hypothalamic-pituitary-adrenal axis in patients with adrenocortical carcinoma.
Reimondo G; Puglisi S; Zaggia B; Basile V; Saba L; Perotti P; De Francia S; Volante M; Zatelli MC; Cannavò S; Terzolo M
Eur J Endocrinol; 2017 Oct; 177(4):361-367. PubMed ID: 28780517
[TBL] [Abstract][Full Text] [Related]
26. Targeting heterogeneity of adrenocortical carcinoma: Evaluation and extension of preclinical tumor models to improve clinical translation.
Hantel C; Shapiro I; Poli G; Chiapponi C; Bidlingmaier M; Reincke M; Luconi M; Jung S; Beuschlein F
Oncotarget; 2016 Nov; 7(48):79292-79304. PubMed ID: 27764813
[TBL] [Abstract][Full Text] [Related]
27. Adrenocortical carcinoma.
Baudin E;
Endocrinol Metab Clin North Am; 2015 Jun; 44(2):411-34. PubMed ID: 26038209
[TBL] [Abstract][Full Text] [Related]
28. New perspectives for mitotane treatment of adrenocortical carcinoma.
Puglisi S; Calabrese A; Basile V; Pia A; Reimondo G; Perotti P; Terzolo M
Best Pract Res Clin Endocrinol Metab; 2020 May; 34(3):101415. PubMed ID: 32179008
[TBL] [Abstract][Full Text] [Related]
29. Morphofunctional effects of mitotane on mitochondria in human adrenocortical cancer cells.
Poli G; Guasti D; Rapizzi E; Fucci R; Canu L; Bandini A; Cini N; Bani D; Mannelli M; Luconi M
Endocr Relat Cancer; 2013 Aug; 20(4):537-50. PubMed ID: 23722227
[TBL] [Abstract][Full Text] [Related]
30. Mitotane sensitizes adrenocortical cancer cells to ionizing radiations by involvement of the cyclin B1/CDK complex in G2 arrest and mismatch repair enzymes modulation.
Cerquetti L; Sampaoli C; Amendola D; Bucci B; Misiti S; Raza G; De Paula U; Marchese R; Brunetti E; Toscano V; Stigliano A
Int J Oncol; 2010 Aug; 37(2):493-501. PubMed ID: 20596677
[TBL] [Abstract][Full Text] [Related]
31. Mitotane increases the radiotherapy inhibitory effect and induces G2-arrest in combined treatment on both H295R and SW13 adrenocortical cell lines.
Cerquetti L; Bucci B; Marchese R; Misiti S; De Paula U; Miceli R; Muleti A; Amendola D; Piergrossi P; Brunetti E; Toscano V; Stigliano A
Endocr Relat Cancer; 2008 Jun; 15(2):623-34. PubMed ID: 18509009
[TBL] [Abstract][Full Text] [Related]
32. Mutational analyses of epidermal growth factor receptor and downstream pathways in adrenocortical carcinoma.
Hermsen IG; Haak HR; de Krijger RR; Kerkhofs TM; Feelders RA; de Herder WW; Wilmink H; Smit JW; Gelderblom H; de Miranda NF; van Eijk R; van Wezel T; Morreau H
Eur J Endocrinol; 2013 Jul; 169(1):51-8. PubMed ID: 23585556
[TBL] [Abstract][Full Text] [Related]
33. Mitotane therapy in adrenocortical cancer induces CYP3A4 and inhibits 5α-reductase, explaining the need for personalized glucocorticoid and androgen replacement.
Chortis V; Taylor AE; Schneider P; Tomlinson JW; Hughes BA; O'Neil DM; Libé R; Allolio B; Bertagna X; Bertherat J; Beuschlein F; Fassnacht M; Karavitaki N; Mannelli M; Mantero F; Opocher G; Porfiri E; Quinkler M; Sherlock M; Terzolo M; Nightingale P; Shackleton CH; Stewart PM; Hahner S; Arlt W
J Clin Endocrinol Metab; 2013 Jan; 98(1):161-71. PubMed ID: 23162091
[TBL] [Abstract][Full Text] [Related]
34. Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane.
van Koetsveld PM; Vitale G; Feelders RA; Waaijers M; Sprij-Mooij DM; de Krijger RR; Speel EJ; Hofland J; Lamberts SW; de Herder WW; Hofland LJ
Endocr Relat Cancer; 2013 Jun; 20(3):443-54. PubMed ID: 23507702
[TBL] [Abstract][Full Text] [Related]
35. Inhibition of Human Adrenocortical Cancer Cell Growth by Temozolomide in Vitro and the Role of the MGMT Gene.
Creemers SG; van Koetsveld PM; van den Dungen ES; Korpershoek E; van Kemenade FJ; Franssen GJ; de Herder WW; Feelders RA; Hofland LJ
J Clin Endocrinol Metab; 2016 Dec; 101(12):4574-4584. PubMed ID: 27603910
[TBL] [Abstract][Full Text] [Related]
36. Tissue Expression and Pharmacological In Vitro Analyses of mTOR and SSTR Pathways in Adrenocortical Carcinoma.
Germano A; Rapa I; Duregon E; Votta A; Giorcelli J; Buttigliero C; Scagliotti GV; Volante M; Terzolo M; Papotti M
Endocr Pathol; 2017 Jun; 28(2):95-102. PubMed ID: 28271381
[TBL] [Abstract][Full Text] [Related]
37. Changes in total and acylated ghrelin levels during mitotane treatment in patients with adrenocortical carcinoma.
Komarowska H; Ruciński M; Fichna M; Bromińska B; Iżycki D; Czarnywojtek A; Ruchała M
Pol Arch Intern Med; 2019 Aug; 129(7-8):469-475. PubMed ID: 31169262
[TBL] [Abstract][Full Text] [Related]
38. Mitotane for adrenocortical carcinoma treatment.
Hahner S; Fassnacht M
Curr Opin Investig Drugs; 2005 Apr; 6(4):386-94. PubMed ID: 15898346
[TBL] [Abstract][Full Text] [Related]
39. Lack of long-lasting effects of mitotane adjuvant therapy in a mouse xenograft model of adrenocortical carcinoma.
Doghman M; Lalli E
Mol Cell Endocrinol; 2013 Dec; 381(1-2):66-9. PubMed ID: 23906534
[TBL] [Abstract][Full Text] [Related]
40. Exquisite sensitivity of adrenocortical carcinomas to induction of ferroptosis.
Belavgeni A; Bornstein SR; von Mässenhausen A; Tonnus W; Stumpf J; Meyer C; Othmar E; Latk M; Kanczkowski W; Kroiss M; Hantel C; Hugo C; Fassnacht M; Ziegler CG; Schally AV; Krone NP; Linkermann A
Proc Natl Acad Sci U S A; 2019 Oct; 116(44):22269-22274. PubMed ID: 31611400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]